H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Neoleukin Therapeutics (NLTX – Research Report) today and set a price target of $22.00. The company’s shares closed last Wednesday at $11.89.
According to TipRanks.com, Burns is a 5-star analyst with an average return of 46.3% and a 75.0% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neoleukin Therapeutics with a $22.67 average price target, a 92.6% upside from current levels. In a report issued on November 9, Mizuho Securities also maintained a Buy rating on the stock with a $21.00 price target.
The company has a one-year high of $18.13 and a one-year low of $2.79. Currently, Neoleukin Therapeutics has an average volume of 203.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.